Microarray-based prediction of cytotoxicity of tumor cells to arsenic trioxide

Cancer Genomics and Proteomics

Volumn 1, Issue 5-6, 2004, Pages 363-370

  Efferth, Thomas ^a   Kaina, Bernd ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Chemotherapy; Drug resistance; Hierarchical cluster analysis; Microarrays

Indexed keywords

EID: 20444390332     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Miller WH jr, Schipper HM, Lee JS, Singer J and Waxman S: Mechanisms of action of arsenic trioxide. Cancer Res 62: 3893-3903, 2002.
2. Klaassen CD: Heavy metals and heavy-metal antagonists. In: JG Hardman, AG Gilman and LE Limbird (eds.) Goodman and Gilman's The Pharmacological Basis of Therapeutics, pp. 1649-1672. New York: McGraW-HILL, 1996.
3. Haller JS: Therapeutic mule: the use of arsenic in the nineteenth century materia medica. Pharmacy in History 17: 87-100, 1975.
4. Chan PC and Huff J: Arsenic carcinogenesis in animals and in humans: mechanistic, experimental, and epidemiological evidence. J Environ Sci Health Part C Environ Carcinog Ecotoxicol Rev C15: 83-122, 1997.
5. Knowles PC and Benson AA: The biogeochemistry of arsenic. Trends Biochem Sci 8: 178-180, 1983.
6. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z and Wang ZY: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360, 1997.
7. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutre S, Dahlberg S, Ellison R and Warrell RP Jr: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19: 3852-3860, 2001.
8. Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY and Chen Z: In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PMLRAR /PML proteins. Blood 88: 1052-1061, 1996.
9. Huang XJ, Wiernik PH, Klein RS and Gallagher RE: Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases. Med Oncol 16: 58-64, 1999.
10. Anderson KC, Boise LH, Louie R and Waxman S: Arsenic trioxide in multiple myeloma: rationale and future directions. Cancer J 8: 12-25, 2002.
11. Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, Chauhan D, Munshi NC, Waxman S and Anderson KC: Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 1: 851-860, 2002.
12. Liu Q, Hilsenbeck S and Gazitt Y: Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 101: 4078-4087, 2003.
13. Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell RP Jr and Rafii S: Arsenic trioxide induces dose-and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 96: 1525-1530, 2000.
14. Hartwig A, Blessing H, Schwerdtle and Walter I: Modulation of DNA repair by arsenic and selenium compounds. Toxicology 193: 161-169, 2003.
15. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH and Boyd MR: Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48: 589-601, 1998.
16. Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A and Boyd MR: Comparison of in vitro anticancer-drug- screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82: 1113-1118, 1990.
17. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO and Weinstein JN: A gene expression database for the molecular pharmacology of cancer. Nat Genet 24: 236-244, 2000.
18. Wosikowski K, Schuurhuis D, Johnson K, Paull KD, Myers TG, Weinstein JN and Bates SE: Identification of epidermal growth factor receptor and erbB2 pathway inhibitors by correlation with gene expression patterns. J Natl Cancer Inst 89: 1505-1515, 1997.
19. Hochberg Y and Benjamini Y: More powerful procedures for multiple significance testing. Stat Med 9: 811-818, 1990.
20. Reiner A, Yekutieli D and Benjamini Y: Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 19: 368-375, 2003.
21. Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, Weber HO, Hengstler JG, Halatsch ME, Volm M, Tew KD, Ross DD and Funk JO: Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol 64: 382-394, 2003.
22. Wu MM, Chiou HY, Ho IC, Chen CJ and Lee TC: Gene expression of inflammatory molecules in circulating lymphocytes from arsenic-exposed human subjects. Environ Health Perspect 111: 1429-1438, 2003.
23. Ramirez P, Del Razo LM, Gutierrez-Ruiz MC and Gonsebatt ME: Arsenite induces DNA-protein crosslinks and cytokeratin expression in the WRL-68 human hepatic cell line. Carcinogenesis 21: 701-706, 2000.
24. Yih LH, Peck K and Lee TC: Changes in gene expression profiles of human fibroblasts in response to sodium arsenite treatment. Carcinogenesis 23: 867-876, 2002.
25. Bae DS, Handa RJ, Yang RS and Campain JA: Gene expression patterns as potential molecular biomarkers for malignant transformation in human keratinocytes treated with MNNG, arsenic, or a metal mixture. Toxicol Sci 74: 32-42, 2003.
26. Lin S, Del Razo LM, Styblo M, Wang C, Cullen WR and Thomas DJ: Arsenicals inhibit thioredoxin reductase in cultured rat hepatocytes. Chem Res Toxicol 14: 305-311, 2001.
27. Ma X, Hu J, Lindner DJ and Kalvakolanu DV: Mutational analysis of human thioredoxin reductase 1. Effects on p53-mediated gene expression and interferon and retinoic acidinduced cell death. J Biol Chem 277: 22460-22468, 2002.
28. Anestal K and Arner ES: Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine. J Biol Chem 278: 15966-15972, 2003.
29. Fowler BA, Woods JS, Squibb KS and Davidian NM: Alteration of hepatic mitochondrial aldehyde dehydrogenase activity by sodium arsenate: the relationship to mitochondrial-microsomal oxidative interactions. Exp Mol Pathol 37: 351-357, 1982.
30. Tsai SH, Liang YC, Chen L, Ho FM, Hsieh MS and Lin JK: Arsenite stimulates cyclooxygenase-2 expression through activating IÎ B kinase and nuclear factor Î B in primary and ECV304 endothelial cells. J Cell Biochem 84: 750-758, 2002.
31. Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidereit C, Bommert K and Dörken B: Inhibition of NF-Î B essentially contributes to arsenic-induced apoptosis. Blood 102: 1028-1034, 2003.
32. Wang H, Liu S, Lu X, Zhao X, Chen S and Li X: Gene expression profile changes in NB4 cells induced by realgar. Chin Med J (Engl) 16: 1074-1077, 2003.
33. He T, Stepulak A, Holmstrom TH, Omary MB and Eriksson JE: The intermediate filament protein kinase 8 is a novel cytoplasmic substrate for c-Jun N-terminal kinase. J Biol Chem 277: 10767-10774, 2002.
34. Hirota K, Matsui M, Murata M, Takashima Y, Cheng FS, Itoh T, Fukuda K and Yodoi J: Nucleoredoxin, glutaredoxin, and thioredoxin differentially regulate NF-Î B, AP-1, and CREB activation in HEK293 cells. Biochem Biophys Res Commun 274: 177-182, 2000.
35. Erratum in: Biochem Biophys Res Commun 275: 247, 2000.
36. Loging WT and Reisman D: Elevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53. Cancer Epidemiol Biomarkers Prev 8: 1011-1016, 1999.
37. Hu ZB, Minden MD, McCulloch EA and Stahl J: Regulation of drug sensitivity by ribosomal protein S3a. Blood 95: 1047-1055, 2000.
38. Erratum in: Blood 96: 1632, 2000.
39. Lopez CD, Martinovsky G and Naumovski L: Inhibition of cell death by ribosomal protein L35a. Cancer Lett 180: 195-202, 2002.
40. Quash G, Fournet G, Chantepie J, Gore J, Ardiet C, Ardail D, Michal Yand Reichert U: Novel competitive irreversible inhibitors of aldehyde dehydrogenase (ALDH1): restoration of chemosensitivity of L1210 cells overexpressing ALDH1 and induction of apoptosis in BAF3 cells overexpressing bcl2. Biochem Pharmacol 64: 1279-1292, 2002.
41. Yoon KA, Nakamura Y and Arakawa H: Identification of ALDH4 as a p53-inducible gene and its protective role in cellular stresses. J Hum Genet 49: 134-140, 2004.
42. Cao Y and Prescott SM: Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 190: 279-286, 2002.
43. Bell SM, Shaw M, Jou Y-S, Myers RM and Knowles MA: Identification and characterization of the human homologue of SH3BP2, an SH3 binding domain protein within a common region of deletion at 4p16.3 involved in bladder cancer. Genomics 44: 163-170, 1997.
44. Attardi LD, Reczek EE, Cosmas C, Demicco EG, McCurrach ME, Lowe SW and Jacks T: PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes Dev 14: 704-718, 2000.
45. Erratum in: Genes Dev 14: 1835, 2000.
46. Shiina H, Igawa M, Breault J, Ribeiro-Filho L, Pookot D, Urakami S, Terashima M, Deguchi M, Yamanaka M, Shirai M, Kaneuchi M, Kane CJ and Dahiya R: The human T-cell factor-gene splicing isoforms, Wnt signal pathway, and apoptosis in renal cell carcinoma. Clin Cancer Res 9: 2121-2132, 2003.
47. Rother K, Johne C, Spiesbach K, Haugwitz U, Tschop K, Wasner M, Klein-Hitpass L, Moroy T, Mossner J and Engeland K: Identification of Tcf-4 as a transcriptional target of p53 signalling. Oncogene 23: 3376-3384, 2004.
48. Alexander CM, Reichsman F, Hinkes MT, Lincecum J and Becker KA, Cumberledge S and Bernfield M: Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nature Genet 25: 329-332, 2000.
49. Dhodapkar MV, Abe E, Theus A, Lacy M, Langford JK, Barlogie B and Sanderson RD: Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood 91: 2679-2688, 1998.
50. Peukert K, Staller P, Schneider A, Carmichael G, Hanel F and Eilers M: An alternative pathway for gene regulation by Myc. EMBO J 16: 5672-5686, 1997.
51. Vousden KH: Switching from life to death: the Miz-ing link between Myc and p53. Cancer Cell 2: 351-352, 2002.
52. Sobel A: Stathmin: a relay phosphoprotein for multiple signal transduction? Trends Biochem Sci 16: 301-305, 1991.
53. Gavet O, Ozon S, Manceau V, Lawler S, Curmi P and Sobel A: The stathmin phosphoprotein family: intracellular localization and effects on the microtubule network. J Cell Sci 111: 3333-3346, 1998.
54. Iancu C, Mistry SJ, Arkin S and Atweh GF: Taxol and antistathmin therapy: a synergistic combination that targets the mitotic spindle. Cancer Res 60: 3537-3541, 2000.
55. Moretti A, Weig H-J, Ott T, Seyfarth M, Holthoff H-P, Grewe D, Gillitzer A, Bott-Flugel L, Schomig A, Ungerer M and Laugwitz K-L: Essential myosin light chain as a target for caspase-3 in failing myocardium. Proc Natl Acad Sci USA 89: 11860-11865, 2002.
56. Mayo MW and Baldwin AS: The transcription factor NF-Î B: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 1470: M55-62, 2000.
57. Monney L, Otter I, Olivier R, Ozer HL, Haas AL, Omura S and Borner C: Defects in the ubiquitin pathway induce caspaseindependent apoptosis blocked by Bcl-2. J Biol Chem 273: 6121-6131, 1998.
58. Seo M, Cho CH, Lee YI, Shin EY, Park D, Bae CD, Lee JW, Lee ES and Juhnn YS: Cdc42-dependent mediation of UVinduced p38 activation by G protein betagamma subunits. J Biol Chem 279: 17366-17375, 2004.
59. Chen S, Mantei N, Dong L and Schachner M: Prevention of neuronal cell death by neural adhesion molecules L1 and CHL1. J Neurobiol 38: 428-439, 1999.